title: Limitation and potential hazards of MAOI's for the treatment of depressive symptoms in abstinent alcoholics.
authors.affiliation: Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06519.
authors.forename: R S
authors.initials: RS
authors.lastname: Schottenfeld
authors.forename: S S
authors.initials: SS
authors.lastname: O'Malley
authors.forename: L
authors.initials: L
authors.lastname: Smith
authors.forename: B J
authors.initials: BJ
authors.lastname: Rounsaville
authors.forename: J H
authors.initials: JH
authors.lastname: Jaffe
mesh_terms: D000328:Adult; D000437:Alcoholism / Q000150:complications* / Q000534:rehabilitation; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D010624:Phenelzine / Q000009:adverse effects; D011567:Psychiatric Department, Hospital; D011569:Psychiatric Status Rating Scales; D011897:Random Allocation; D013695:Temperance; D014191:Tranylcypromine / Q000009:adverse effects
chemical_list: D008996:Monoamine Oxidase Inhibitors; D014191:Tranylcypromine; D010624:Phenelzine